Dura Pharmaceuticals, Inc. v. Broudo
Citation: 544 U.S. 336 (Supreme Court, 2005)
Facts
Dura Pharmaceuticals made optimistic public statements about its prospects of obtaining FDA approval for a new drug. Investors bought Dura stock at inflated prices. When FDA approval was denied, the stock price dropped. Plaintiffs filed a securities fraud class action under Rule 10b-5, arguing that they suffered losses because they paid inflated prices for Dura stock. The Ninth Circuit held that alleging an “inflated purchase price” was sufficient to plead loss causation.
Issue
Whether a securities fraud plaintiff satisfies the loss causation requirement of a Rule 10b-5 claim by merely alleging that the price paid for a security was artificially inflated at the time of purchase.
Holding
No. The Supreme Court reversed the Ninth Circuit unanimously, holding that loss causation requires more than an allegation of an inflated purchase price. A plaintiff must allege and prove that the misrepresentation caused the subsequent economic loss — typically by alleging a corrective disclosure that caused the price to fall.
Rule
Loss causation — the causal link between the material misrepresentation and the plaintiff’s actual economic loss — is a required element of a 10b-5 claim (analogous to proximate causation in tort). An inflated purchase price does not itself establish loss causation because the inflation may reverse before the plaintiff sells (through market correction, news events, or other causes), leaving the plaintiff with no net loss attributable to the fraud. A plaintiff typically must plead that the truth was revealed through a corrective disclosure that caused the stock price to fall, and that the plaintiff suffered losses in connection with that revelation.
Significance
Dura is the leading case on loss causation and is central to understanding the elements of a private securities fraud action under Rule 10b-5 and the PSLRA. The case tightened pleading requirements for securities class actions and clarified that securities fraud is not a free insurance policy against stock losses — plaintiffs must connect their specific losses to the alleged fraud. The corrective disclosure requirement has generated substantial litigation about what qualifies as a corrective disclosure and whether partial disclosures suffice.